Roivant Reports Financial Results for the First Quarter Ended June 30, 2025, and Provides Business UpdateGlobeNewsWire • 08/11/25
Roivant to Report Financial Results for the First Quarter Ended June 30, 2025, and Provide Business Update on Monday, August 11, 2025GlobeNewsWire • 07/28/25
Pulmovant Announces Publication of Pharmacokinetics and Lung Deposition Data for Inhaled Mosliciguat in Clinical PharmacokineticsGlobeNewsWire • 06/16/25
Roivant and Priovant to Host Investor Video Conference at 1:00 PM ET on Tuesday, June 17 on Brepocitinib and the Unmet Medical Need in DermatomyositisGlobeNewsWire • 06/09/25
Roivant Sciences Ltd. (ROIV) Reports Q4 Loss, Lags Revenue EstimatesZacks Investment Research • 05/29/25
Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2025, and Provides Business UpdateGlobeNewsWire • 05/29/25
Roivant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2025 and Provide Business Update on Thursday, May 29, 2025GlobeNewsWire • 05/15/25
Immunovant Crumbles After Roivant Sweeps Out Its C-Suite, Unveils Strategic ShiftInvestors Business Daily • 04/21/25
Immunovant Announces Next Phase of Growth with Roivant Including Changes to its Leadership Team and Additional Indications Sjögren's Disease (SjD) and Cutaneous Lupus Erythematosus (CLE) for IMVT-1402GlobeNewsWire • 04/21/25
Roivant, Immunovant Succeed In Phase 3. But There's A Twist — And Shares Tumbled.Investors Business Daily • 03/19/25
Roivant Announces Positive Results for Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) StudiesGlobeNewsWire • 03/19/25
Roivant to Host Investor Webcast at 8:00 AM ET on Wednesday, March 19 to Review Results from Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) ProgramsGlobeNewsWire • 03/18/25
Wall Street Analysts Believe Montes Archimedes Acquisition (ROIV) Could Rally 60%: Here's is How to TradeZacks Investment Research • 03/12/25
Genevant Sciences and Arbutus Biopharma Initiate International Patent Infringement Enforcement Actions Against ModernaGlobeNewsWire • 03/03/25
All You Need to Know About Montes Archimedes Acquisition (ROIV) Rating Upgrade to BuyZacks Investment Research • 02/14/25
Roivant Sciences Ltd. (ROIV) Reports Q3 Loss, Tops Revenue EstimatesZacks Investment Research • 02/10/25
Roivant Reports Financial Results for the Third Quarter Ended December 31, 2024, and Provides Business UpdateGlobeNewsWire • 02/10/25
Roivant: Telavant-Like Success Will Be Challenging To Replicate (Rating Downgrade)Seeking Alpha • 02/05/25